Citius Pharmaceuticals, Inc. (CTXR) Financial Statements (2026 and earlier)

Company Profile

Business Address 11 COMMERCE DRIVE
CRANFORD, NJ 07016
State of Incorp. NV
Fiscal Year End September 30
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2026
MRQ
12/31/2025
MRQ
9/30/2025
9/30/2024
9/30/2023
9/30/2022
9/30/2021
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments7,7214,2523,25226,48141,71270,073
Cash and cash equivalent7,7214,2523,25226,48141,71270,073
Receivables4,049     
Inventory, net of allowances, customer advances and progress billings22,63922,2878,269   
Inventory22,63922,2878,269   
Prepaid expense3,5351,3952,7007,8902,8532,741
Total current assets:37,94527,93414,22134,37044,56472,814
Noncurrent Assets
Operating lease, right-of-use asset835819246454646823
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization    147
Intangible asset, including goodwill, after accumulated amortization    9,3479,3479,347
Goodwill    9,3479,3479,347
Other noncurrent assets101,611102,185102,185   
Other undisclosed noncurrent assets    59,43859,43859,438
Total noncurrent assets:102,447103,004102,43169,24169,43569,615
TOTAL ASSETS:140,392130,938116,652103,611113,999142,429
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities15,71517,8844,9443,4044,3333,805
Employee-related liabilities✕✕✕✕✕1,7621,906
Accounts payable11,02113,6944,9272,9271,1651,277
Accrued liabilities4,6934,190174761,405622
Debt 1,0001,000    
Other undisclosed current liabilities21,49226,03130,8712,375197177
Total current liabilities:38,20744,91535,8155,7794,5303,982
Noncurrent Liabilities
Long-term debt and lease obligation:     481678
Liabilities, other than long-term debt8,7178,4966,7356,4015,5624,986
Deferred income tax liabilities8,0357,7716,7146,1385,5624,986
Operating lease, liability68272521263481678
Total noncurrent liabilities:8,7178,4966,7356,4016,0435,664
Total liabilities:46,92453,41042,55012,18010,5739,646
Equity
Equity, attributable to parent79,95867,55070,07790,831102,826132,182
Common stock22187159146146
Additional paid in capital326,961306,336271,440252,904232,368228,084
Accumulated deficit(247,025)(238,804)(201,370)(162,231)(129,688)(96,048)
Equity, attributable to noncontrolling interest13,5109,9774,024600600600
Total equity:93,46877,52874,10291,431103,426132,783
TOTAL LIABILITIES AND EQUITY:140,392130,938116,652103,611113,999142,429

Income Statement (P&L) ($ in thousands)

3/31/2026
TTM
12/31/2025
TTM
9/30/2025
9/30/2024
9/30/2023
9/30/2022
9/30/2021
Revenues3,944   9090
Other income      60
Cost of revenue
(Other undisclosed Cost of revenue)
(789)     
Gross profit:3,155   9090
Operating expenses(40,660)(38,526)(41,996)(36,732)(33,316)(23,532)
Other undisclosed operating loss     (90)(90)
Operating loss:(37,505)(38,526)(41,996)(36,732)(33,316)(23,532)
Nonoperating income (expense)(291)(158)3,1464,765251477
Investment income, nonoperating1331107581,179251262
Other nonoperating income    3,586  
Interest and debt expense(325)(268)2,388  322
Loss from continuing operations before equity method investments, income taxes:(38,121)(38,951)(36,462)(31,967)(33,065)(22,732)
Other undisclosed income (loss) from continuing operations before income taxes325268(2,388)   
Loss from continuing operations before income taxes:(37,796)(38,683)(38,850)(31,967)(33,065)(22,732)
Income tax expense(1,057)(1,057)(576)(576)(576)(1)
Loss from continuing operations:(38,853)(39,740)(39,426)(32,543)(33,641)(22,733)
Loss before gain (loss) on sale of properties:✕✕✕✕✕(33,641)(22,733)
Other undisclosed net loss      (321)
Net loss:(38,853)(39,740)(39,426)(32,543)(33,641)(23,054)
Net income attributable to noncontrolling interest2,9662,306287   
Other undisclosed net loss attributable to parent (595)     
Net loss attributable to parent:(36,481)(37,434)(39,139)(32,543)(33,641)(23,054)
Preferred stock dividends and other adjustments      (1,451)
Other undisclosed net income (loss) available to common stockholders, basic 595 (1,047)(1,151)  
Net loss available to common stockholders, diluted:(35,886)(37,434)(40,186)(33,694)(33,641)(24,505)

Comprehensive Income ($ in thousands)

3/31/2026
TTM
12/31/2025
TTM
9/30/2025
9/30/2024
9/30/2023
9/30/2022
9/30/2021
Net loss:(38,853)(39,740)(39,426)(32,543)(33,641)(23,054)
Comprehensive loss:(38,853)(39,740)(39,426)(32,543)(33,641)(23,054)
Comprehensive income, net of tax, attributable to noncontrolling interest2,9662,306287   
Comprehensive loss, net of tax, attributable to parent:(35,886)(37,434)(39,139)(32,543)(33,641)(23,054)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: